Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00179725 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma
A Phase 1 study, sponsored by Celgene Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT00179725 is a Phase 1 study that was terminated before completion, run by Celgene Corporation. The registered enrollment target is 60 participants.
The verdict
NCT00179725, a Phase 1 study, was terminated before completion, sponsored by Celgene Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
Phase I will determine the MTD and evaluated the safety profile of oral lenalidomide on days 1-21 when given with liposomal doxorubicin on day 1 of every 28 day cycle Phase II will commence once the MTD is established, additional subjects will be enrolled and receive oral lenalidomide on days 1-21 with liposomal doxorubicinon day 1 in 28 day cycles until disease progression is documented.
Interventions
- DRUG liposomal doxorubicin
- DRUG CC-5013
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2005-11 |
| Est. Completion | 2007-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00179725
The ClinicalTrials.gov registry entry for NCT00179725 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene Corporation, which has 40 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which liposomal doxorubicin is the first listed.
NCT00179725 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00179725 about?
NCT00179725 is a clinical study titled "Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma". Phase I will determine the MTD and evaluated the safety profile of oral lenalidomide on days 1-21 when given with liposomal doxorubicin on day 1 of every 28 day cycle Phase II will commence once the MTD is established, additional subjects will be enrolled and receive oral lenalidomide on days 1-21 w...
What is the current status of trial NCT00179725?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2005-11. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00179725?
The interventions under investigation include: liposomal doxorubicin (DRUG), CC-5013 (DRUG).
Who is sponsoring clinical trial NCT00179725?
This trial is sponsored by Celgene Corporation, which has 40 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.